AUREALIS THERAPEUTICS
They exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16. Their goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.
AUREALIS THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Kuopio, Eastern Finland, Finland
Country:
Finland
Website Url:
http://www.aurealistherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
10 M USD
Technology used in webpage:
Google Maps U.S. Server Location
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Leuvas Therapeutics
Leuvas Therapeutics is a recently established biopharmaceutical company.
MC2 Therapeutics
MC2 Therapeutics is a privately held emerging pharmaceutical company.
Current Employees Featured
Investors List
Zhejiang Huahai Pharmaceutical
Zhejiang Huahai Pharmaceutical investment in Series A - Aurealis Therapeutics
Tesi
Tesi investment in Series A - Aurealis Therapeutics
Lynx Capital
Lynx Capital investment in Series A - Aurealis Therapeutics
Official Site Inspections
http://www.aurealistherapeutics.com Semrush global rank: 12.64 M Semrush visits lastest month: 90
- Host name: aurealistherapeutics.com
- IP address: 206.189.123.63
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
More informations about "Aurealis Therapeutics"
About - Aurealis Therapeutics
Before joining Aurealis Therapeutics, Igor worked as a project leader and project manager for a biotechnology center in Berlin, for a research department of the Japanese company Snow …See details»
Aurealis Therapeutics | Multi-target cell and gene …
Aurealis 4-in-1 multi-target cell and gene therapy platform is the game-changing solution for complex multi-factorial diseases. Discover how our technology is re-defining the treatment of chronic wounds (diabetic foot ulcers, venous leg …See details»
Aurealis Therapeutics - Crunchbase Company Profile & Funding
Organization. Aurealis Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Aurealis Therapeutics is a swiss …See details»
Aurealis Therapeutics AG – Swiss Biotech
Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company. Our multi-target Bacterial Vector therapy platform, based on genetically modified lactic bacteria, addresses unmet medical needs: Chronic …See details»
Aurealis Therapeutics - LinkedIn
Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses ...See details»
Board - KPY
E-mail: [email protected]. Previous positions: Charles River Finland Oy, Chief Executive Officer; Cerebricon Oy, Chief Executive Officer; Aurealis Pharma AG, Chief …See details»
Aurealis Therapeutics - Overview, News & Similar companies
Aurealis Therapeutics contact info: Phone number: +358 458433550 Website: www.aurealistherapeutics.com What does Aurealis Therapeutics do? Aurealis Therapeutics …See details»
Aurealis Therapeutics - Craft
Aurealis Therapeutics is a company that develops a treatment method for chronic non-healing wounds and other regenerative diseases. Its genetically modified lactic acid bacteria based …See details»
AUREALIS THERAPEUTICS - Swiss Biotech Day
CEO Juha Yrjänheikki, [email protected] COO Laurent Décory, [email protected]. Linkedin 3 - iconmonstr. World outline. Title: AUREALIS …See details»
Aurealis Therapeutics - PitchBook
Aurealis Therapeutics General Information Description. Developer of a cell and gene therapy platform designed to heal multifactorial diseases. The company's platform facilitates a novel …See details»
Aurealis Pharma announces 7.8MCHF financing to advance …
Feb 11, 2019 The most visible changes are the new name, new web page at www.aurealistherapeutics.com, and new email addresses. AUP-16 clinical plan AUP-16 first-in …See details»
Aurealis News | Aurealis Therapeutics
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, announced today the successful completion of …See details»
Aurealis Therapeutics | Startup Profile and Investments
Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company that focuses on developing multi-target cell and gene therapies to address unmet medical needs in areas …See details»
Aurealis Pharma - Craft
Aurealis Pharma has 5 employees across 2 locations and $5.71 m in total funding,. See insights on Aurealis Pharma including office locations, competitors, revenue, financials, executives, …See details»
Aurealis Therapeutics featured in Nordic Life Science News 2023
Jul 14, 2023 Email: [email protected]. Share the news: Prev Previous Aurealis Therapeutics strengthens its Board of Directors by appointing Jean de Gunzburg as a new …See details»
Aurealis Therapeutics - VentureRadar
"Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non …See details»
Aurealis Therapeutics: USD 10 million raised for multi-factor …
Mar 30, 2023 Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a …See details»
Aurealis Therapeutics is leading the world in developing a new …
Oct 21, 2022 Kuopio-based Aurealis Therapeutics has developed a cell and gene therapy platform with a 4-in-1 effect that helps activate the human immune system against severe …See details»
Pipeline and Science - Aurealis Therapeutics
Lead product: AUP-16. Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients was completed with excellent results.We received approval for Phase 2 clinical study in DFUs in …See details»
Aurealis Therapeutics raises CHF8 million - startupticker.ch
Nov 15, 2024 Aurealis’ cell and gene therapies allow to modulate tissue microenvironment and tackle complex multi-factorial diseases such as chronic wounds, cancers, and inflammation. …See details»